Literature DB >> 1348891

Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma.

H P Elsässer1, U Lehr, B Agricola, H F Kern.   

Abstract

From a liver metastasis of a human pancreatic adenocarcinoma, we have established cell lines for studying the cell biology of this tumor. We obtained two cell lines with different morphological, chromosomal and functional properties. One of them, named PaTu 8988s, revealed a solid growth in nude mouse xenografts with cells exhibiting only occasional polar organisation of the cytoplasm. In general, no apical or basolateral plasma membrane domains could be distinguished and the sparse organelles were randomly distributed throughout the cytoplasm. Secretory products, such as mucin, were weakly stained histochemically or were completely absent. Transglutaminase (TGase) activity used as a marker for cellular differentiation was low in these cells. The other cell line, named PaTu 8988t, grew tumors composed of tubular structures when injected subcutaneously into nude mice. Cells were polarized with distinct apical and basolateral plasma membranes and the cytoplasmatic organelles were arranged with the nucleus in the lower part of the cell, while the apical cytoplasm contained the Golgi complex and numerous secretion granules. A high content of mucin was stained histochemically and transglutaminase activity was ten times higher than in PaTu 8988s. Comparing the chromosome number per metaphase plate, both cell lines showed a major peak, with 45-55 chromosomes per metaphase plate in PaTu 8988s and about 110-120 chromosomes per metaphase plate in PaTu 8988t. When the two cell lines were injected intravenously into the tail vein of nude mice, only PaTu 8988s developed metastases localized exclusively in the lung, whereas PaTu 8988t produced no metastases in any organ. We conclude, that two cell lines exhibiting different grades of differentiation as well as a different potency to metastasize can be established from the same primary tumor, and that these cell lines represent a suitable model for further study of the cell biology of human pancreatic adenocarcinoma.

Entities:  

Mesh:

Year:  1992        PMID: 1348891     DOI: 10.1007/bf02890431

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  28 in total

1.  Expression and potential role of E-cadherin in pancreatic carcinoma.

Authors:  R J Weinel; K Neumann; O Kisker; A Rosendahl
Journal:  Int J Pancreatol       Date:  1996-02

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

3.  Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.

Authors:  Christine Mehner; Erin Miller; Davitte Khauv; Aziza Nassar; Ann L Oberg; William R Bamlet; Lizhi Zhang; Jens Waldmann; Evette S Radisky; Howard C Crawford; Derek C Radisky
Journal:  Mol Cancer Res       Date:  2014-05-21       Impact factor: 5.852

4.  YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.

Authors:  Bo Tu; Jun Yao; Sammy Ferri-Borgogno; Jun Zhao; Shujuan Chen; Qiuyun Wang; Liang Yan; Xin Zhou; Cihui Zhu; Seungmin Bang; Qing Chang; Christopher A Bristow; Ya'an Kang; Hongwu Zheng; Huamin Wang; Jason B Fleming; Michael Kim; Timothy P Heffernan; Giulio F Draetta; Duojia Pan; Anirban Maitra; Wantong Yao; Sonal Gupta; Haoqiang Ying
Journal:  JCI Insight       Date:  2019-11-01

5.  PARI overexpression promotes genomic instability and pancreatic tumorigenesis.

Authors:  Kevin W O'Connor; Donniphat Dejsuphong; Eunmi Park; Claudia M Nicolae; Alec C Kimmelman; Alan D D'Andrea; George-Lucian Moldovan
Journal:  Cancer Res       Date:  2013-02-22       Impact factor: 12.701

6.  BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Audrey Benyamine; Céline Loncle; Etienne Foucher; Juan-Luis Blazquez; Céline Castanier; Anne-Sophie Chrétien; Mauro Modesti; Véronique Secq; Salem Chouaib; Meritxell Gironella; Elena Vila-Navarro; Giuseppe Montalto; Jean-Charles Dagorn; Nelson Dusetti; Juan Iovanna; Daniel Olive
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

7.  Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.

Authors:  L Li; Y-Z Yuan; J Lu; L Xia; Y Zhu; Y-P Zhang; M-M Qiao
Journal:  Gut       Date:  2005-11-15       Impact factor: 23.059

8.  Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential.

Authors:  Mark F Coughlin; Diane R Bielenberg; Guillaume Lenormand; Marina Marinkovic; Carol G Waghorne; Bruce R Zetter; Jeffrey J Fredberg
Journal:  Clin Exp Metastasis       Date:  2012-09-08       Impact factor: 5.150

9.  Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Authors:  Arkadeep Sinha; David Cherba; Heather Bartlam; Elizabeth Lenkiewicz; Lisa Evers; Michael T Barrett; Brian B Haab
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

10.  Characterization of three cloned cell lines from a N-nitrosobis(2-hydroxypropyl)amine-induced transplantable hamster pancreatic ductal adenocarcinoma.

Authors:  T Mori; M Tsutsumi; O Noguchi; K Horiguchi; K Hohnoki; S Okita; F Suzuki; Y Konishi
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.